Last reviewed · How we verify
Lidocaine HCl 2% .
At a glance
| Generic name | Lidocaine HCl 2% . |
|---|---|
| Also known as | ESRACAIN |
| Sponsor | HaEmek Medical Center, Israel |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- OMT for Adhesive Capsulitis (PHASE4)
- Sphenopalatine Ganglion Block for Post-Dural Puncture Headache: A Pilot Randomised Controlled Trial (NA)
- Effects of Different Drugs for Glottic Atomization on Postoperative Sore Throat After Thyroid Surgery (PHASE4)
- Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial (PHASE3)
- Jaw Muscle Pain Post Wisdom Molar Surgery (PHASE2)
- Comparison of the Effectiveness of Exercise, Dry Needling and Interfascial Block Treatments in the Treatment of Myofascial Pain Syndrome (NA)
- Bladder Directed vs. Pelvic Floor Therapy in IC/BPS (PHASE2)
- Opioid Free and Opioid Based Anesthesia in Elective Lumbar Spine Surgery
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lidocaine HCl 2% . CI brief — competitive landscape report
- Lidocaine HCl 2% . updates RSS · CI watch RSS
- HaEmek Medical Center, Israel portfolio CI